Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pulmonary suffusion may also be useful in avoiding later use of drugs by vein that demonstrate no effect on tumors when delivered locally. The Phase 1 portion of the study has been completed.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Przerzuty raka do płuc, szczególnie rak jelita grubego
- •Ogólny stan zdrowia pozwalający na tolerowanie zabiegu (ocena ECOG ≤ 2)
- •Liczba hemoglobiny powyżej 8,0 g/L
- •Liczba płytek krwi powyżej 100 000 na mikroliter
- •Funkcja nerek pozwalająca na oczyszczanie kreatyniny ≥ 30 mL/min
- •Dostateczna pojemność płuc do tolerowania planowanej operacji
- •Główny nowotwór pod kontrolą (stabilny lub zdążający)
- •Możliwość techniczna do usunięcia lub zniszczenia wszystkich guzów w płucach
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Roswell Park Cancer Institute
Buffalo, United States
Trial contact
Kenneth Seastedt
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.